Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Evidence and Use of IVIG for Treating SJS-TEN

Description

The speaker reviews the rationale and evidence for using IVIG as an adjunct treatment for SJS-TEN, emphasizing that SJS and TEN are points on the same immune-mediated disease spectrum driven by CD8+ T cells, NK cells, cytotoxic molecules, and Fas-Fas ligand–mediated keratinocyte apoptosis. IVIG is described as a pooled human plasma product composed mainly of IgG with broad immunomodulatory effects, including neutralizing pathogenic antibodies, inhibiting complement, suppressing inflammatory cytokines, and modulating dendritic cells. The talk highlights additional theoretical benefits in SJS-TEN, such as protection against infection and replacement of protein losses during the catabolic, fluid-depleting phase of illness. Early studies suggested benefit, including the seminal 1998 report linking IVIG to blockade of Fas-mediated apoptosis and a small open-label series showing halted progression and survival in all patients. Subsequent retrospective and prospective studies often found better outcomes with earlier and higher-dose IVIG, with several analyses suggesting that total doses of at least 3 g/kg, and sometimes 4 g/kg, may be associated with improved survival. However, larger observational studies and some meta-analyses showed no clear mortality benefit, especially when lower IVIG doses were used. The speaker concludes that evidence remains low quality and largely observational, but he remains supportive of IVIG when used early, at high dose, and only as an adjunct to best supportive care.

View more

Conclusions

SJS/TEN is best understood as an immune-mediated disease in which cytotoxic T cells and NK cells drive widespread keratinocyte apoptosis.
IVIG has multiple immunomodulatory effects that make it a biologically plausible adjunct treatment for SJS/TEN, including neutralizing pathogenic factors, inhibiting complement, and dampening inflammation.
IVIG may also help patients with TEN by providing immunoprotective antibodies and replacing substantial fluid and protein losses during the acute illness.
The earliest reports and several small studies suggested that IVIG could halt disease progression and improve survival in TEN.
Across the observational literature, better outcomes tend to be associated with earlier IVIG administration.
Higher total IVIG doses appear to be associated with greater survival benefit, while studies using lower doses often fail to show benefit.
Evidence from retrospective cohorts and pooled analyses suggests that doses of at least about 3 g/kg, and possibly 4 g/kg, are more likely to be effective.
Large registry-based studies have not consistently shown a mortality benefit for IVIG overall, highlighting major uncertainty in the evidence base.
The overall evidence for IVIG in SJS/TEN remains low quality because it relies mainly on case reports, small prospective studies, and retrospective analyses.
If IVIG is used, it should be considered only as an adjunct to best supportive care rather than a substitute for it.

Wolkenstein P et al. Lancet 1998; 352: 1586-1589.
Dalakas MC. Neurotherapeutics 2021; 18: 2397-2418.
Fernandez AP, Kerdel F. Dermatol Ther. 2007 Jul-Aug;20(4):288-305.
Prins C et al. Arch Dermatol 2003; 139: 26-32.
Trent JT et al. Arch Dermatol 2003; 139: 39-43.
Schneck J et al. J Am Acad Dermatol 2008;58:33-40.
Ricotti CA, Romanelli P, Kirsern R, French L, Kerdel FA. Medical Management of TEN: Focus on Supportive Care. World Congress of Dermatology Buenos Aires Argentina 3007.